Absci Corp (ABSI) stock: key figures, P/E, revenue and dividend
Industrials · United States · ISIN US00091E1091
Absci Corp financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.80 m USD |
| Operating income | -120.32 m USD |
| EBIT | -114.91 m USD |
| Net income | -115.18 m USD |
| Diluted EPS – continuing operations | -0.84 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
More stocks
- Siltronic (WAF.DE)
- IDT CORP (IDT)
- Wuhu Token Sciences (300088.SZ)
- Taiflex Scientific Co Ltd (8039.TW)
- Sarepta Therapeutics, Inc. (SRPT)
- Shenglan Technology Co Ltd (300843.SZ)
- Monadelphous Group Ltd (MND.AX)
- Uwc Bhd (5292.KL)
- TRINITY INDUSTRIES INC (TRN)
- Malaysian Pacific Industries (3867.KL)
- Xiamen Leading Optics Co Ltd (605118.SS)
- Companhia Paranaense de Energia - COPEL (ELPC)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.